Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Nykode Therapeutics ASFRA:5VB -0.40%48 Debt-to-Equity is 0.03 as of Mar. 2026, which is at its 10-year median of 0.03. GuruFocus rates FRA:5VB with a GF Score™ of 48/100 and a GF Value™ of €0.48 (Possible Value Trap). The stock has 2 warning signs investors should review. Among 967 Biotechnology companies, Nykode Therapeutics AS ranks better than 80.87% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Nykode Therapeutics AS's Debt-to-Equity or its related term are showing as below:
FRA:5VB'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0 Med: 0.03 Max: 0.04
Current: 0.03
During the past 9 years, the highest Debt-to-Equity Ratio of Nykode Therapeutics AS was 0.04. The lowest was 0.00. And the median was 0.03.
FRA:5VB's Debt-to-Equity is ranked better than 80.87% of 967
companies
in the Biotechnology industry
Industry Median: 0.16
vs FRA:5VB: 0.03
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Nykode Therapeutics AS Debt-to-Equity Related Terms
Nykode Therapeutics AS Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Nykode Therapeutics AS's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:5VB vs VRTX, REGN, RVMD: Debt-to-Equity Comparison
For the Biotechnology subindustry, Nykode Therapeutics AS's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nykode Therapeutics AS Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Nykode Therapeutics AS's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Nykode Therapeutics AS's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nykode Therapeutics AS (FRA:5VB) has a Debt-to-Equity of 0.03 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Nykode Therapeutics AS and its competitors. This is near median its historical median of 0.03. According to the industry distribution chart, Nykode Therapeutics AS ranks #185 out of 967 companies in the Biotechnology industry, placing it in the top 19.1%.
Is Nykode Therapeutics AS's Debt-to-Equity too high?
Nykode Therapeutics AS's current Debt-to-Equity of 0.03 is near median its 10-year median of 0.03. The Biotechnology industry median Debt-to-Equity is 0.16. Nykode Therapeutics AS's value of 0.03 is 81.3% below this industry median. Based on the distribution chart, Nykode Therapeutics AS ranks #185 out of 967 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Nykode Therapeutics AS has a GF Score™ of 48/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Nykode Therapeutics AS's Debt-to-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Nykode Therapeutics AS ranks #185 out of 967 companies for Debt-to-Equity. This places Nykode Therapeutics AS in the top 19% of its industry — outperforming the majority of peers. The industry median Debt-to-Equity is 0.16. Nykode Therapeutics AS's value of 0.03 is 81.3% below this benchmark. While the company's 10-year median is 0.03 vs. the industry median of 0.16, Nykode Therapeutics AS has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 967 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nykode Therapeutics AS's current Debt-to-Equity of 0.03 is 81.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Nykode Therapeutics AS and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nykode Therapeutics AS's current Debt-to-Equity is 0.03, which is near median its own 10-year median of 0.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nykode Therapeutics AS stock overvalued right now?
Based on GuruFocus' analysis, Nykode Therapeutics AS (FRA:5VB) is currently considered Possible Value Trap. The stock's GF Value™ is €0.48, compared to a current price of €0.25 — trading 48% below its estimated fair value. The current Debt-to-Equity is 0.03, which is near median its 10-year median of 0.03 and 81.3% below the Biotechnology industry median of 0.16. Nykode Therapeutics AS's overall GF Score™ is 48/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Nykode Therapeutics AS (FRA:5VB), the current Debt-to-Equity is 0.03 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nykode Therapeutics AS (FRA:5VB) Overvalued in 2026?
Based on GuruFocus' analysis, Nykode Therapeutics AS stock appears to be undervalued.
The current stock price of €0.25 is trading 48% below its estimated GF Value™ of €0.48.
GuruFocus considers Nykode Therapeutics AS to be Possible Value Trap.
Key valuation signals for FRA:5VB:
Debt-to-Equity: 0.03 (near median its 10-year median of 0.03)
GF Value™: €0.48 vs. price of €0.25 (48% below fair value)
Industry Position: 81.3% below the Biotechnology median (#185 of 967)
No single metric tells the full story. See the FRA:5VB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nykode Therapeutics AS is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immunotherapies. The company is developing individualized cancer neoantigen vaccines and is using the Vaccibody technology to generate therapeutics to treat cancers with a high unmet medical need using it's modular immunotherapy technology, specifically targeting antigens to Antigen Presenting Cells, which are essential for inducing rapid and long-lasting immune responses. It operates in United States of America.
48GF Score
Get the complete analysis for FRA:5VB
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:5VB has been successfully added to your 
